Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer
- PMID: 12488298
- DOI: 10.1093/annonc/mdg002
Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer
Abstract
Background: It has been suggested that progression of superficial bladder cancer may be regulated at the molecular level by a typical pattern of expression of genes involved in apoptosis. Recently LIVIN, belonging to the inhibitors of apoptosis (IAP) family, has been found to be expressed in most solid tumors, where its expression is suggested to have prognostic significance. No data are available concerning the significance of LIVIN in the progression of bladder tumors.
Patients and methods: In the present paper we used RT-PCR to investigate the expression of LIVIN isoforms alpha and beta, SURVIVIN, BCL-X and BCL-2/BAX expression ratio both in normal and tumoral bladder tissues, and correlated their expression with the emergence of early relapses in a follow-up of 4 years. This study shows that only the alpha isoform of LIVIN, which is not expressed in normal bladder tissue, is expressed in a proportion of tumors with a high risk of relapse.
Results: LIVIN was found in 7/30 patients (23%), SURVIVIN in 9/30 (30%), BCL-2/BAX ratio >1 in 16/30 (53%), BCL-2/BAX expression ratio <1 in 14/30 (46.6%) and BCL-X, only in isoform BCL-X(L), in 11/30 (36.6%). When we evaluated the dependence between each gene expression and relapse free time of patients, we found that LIVIN, high BCL-2/BAX ratio and BCL-X(L), but not SURVIVIN, reached statistical significance in order to predict relapses.
Conclusions: Our findings suggest that LIVIN may be involved in the progression of superficial bladder cancer and used as a marker of early recurrence; while the expression of SURVIVIN cannot be used to identify patients with high risk of relapse.
Similar articles
-
Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.Cancer Lett. 2003 Nov 25;201(2):225-36. doi: 10.1016/s0304-3835(03)00518-4. Cancer Lett. 2003. PMID: 14607338
-
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.J Clin Oncol. 2003 Jan 15;21(2):306-12. doi: 10.1200/JCO.2003.08.066. J Clin Oncol. 2003. PMID: 12525523
-
Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.Urol Oncol. 2009 May-Jun;27(3):277-83. doi: 10.1016/j.urolonc.2008.03.015. Epub 2008 Jun 16. Urol Oncol. 2009. PMID: 18555709
-
Survivin: a promising biomarker for detection and prognosis of bladder cancer.World J Urol. 2008 Feb;26(1):59-65. doi: 10.1007/s00345-007-0219-y. Epub 2007 Oct 26. World J Urol. 2008. PMID: 17962949 Review.
-
Research progress on Livin protein: an inhibitor of apoptosis.Mol Cell Biochem. 2011 Nov;357(1-2):39-45. doi: 10.1007/s11010-011-0873-7. Epub 2011 May 27. Mol Cell Biochem. 2011. PMID: 21617971 Review.
Cited by
-
Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration.J Biol Chem. 2012 Aug 17;287(34):28445-55. doi: 10.1074/jbc.M112.341297. Epub 2012 Jun 18. J Biol Chem. 2012. PMID: 22711539 Free PMC article.
-
Small interfering RNA targeting S100A4 sensitizes non-small-cell lung cancer cells (A549) to radiation treatment.Onco Targets Ther. 2016 Jun 23;9:3753-62. doi: 10.2147/OTT.S106557. eCollection 2016. Onco Targets Ther. 2016. PMID: 27382312 Free PMC article.
-
Targeting IAP proteins for therapeutic intervention in cancer.Nat Rev Drug Discov. 2012 Feb 1;11(2):109-24. doi: 10.1038/nrd3627. Nat Rev Drug Discov. 2012. PMID: 22293567 Review.
-
Expression and clinical significance of livin protein in hepatocellular carcinoma.Dis Markers. 2013;35(5):489-96. doi: 10.1155/2013/781740. Epub 2013 Oct 3. Dis Markers. 2013. PMID: 24223461 Free PMC article.
-
A listing of human tumor antigens recognized by T cells: March 2004 update.Cancer Immunol Immunother. 2005 Mar;54(3):187-207. doi: 10.1007/s00262-004-0560-6. Epub 2004 Aug 7. Cancer Immunol Immunother. 2005. PMID: 15309328 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials